Literature DB >> 30579960

Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform.

Constance Delaby1, Laia Muñoz2, Soraya Torres2, Alícia Nadal3, Nathalie Le Bastard4, Sylvain Lehmann5, Alberto Lleó2, Daniel Alcolea6.   

Abstract

OBJECTIVES: To assess the potential influence of the ratio between the storage tube surface area and the volume of cerebrospinal fluid (CSF) (surface/volume) on the quantifications of four Alzheimer's disease (AD) biomarkers on the Lumipulse G600II automated platform.
METHODS: CSF samples of 10 consecutive patients were stored in 2 ml polypropylene tubes containing four different CSF volumes: 1.5 ml, 1 ml, 0.5 ml and 0.25 ml. Concentration of CSF Aβ1-42, Aβ1-40, t-Tau and p-Tau were measured in all aliquots using the LUMIPULSE G600II automated platform from Fujirebio.
RESULTS: Levels of CSF Aβ1-42 and Aβ1-40 were lower in samples stored with lower volumes (higher surface/volume ratios). This decrease was partly compensated by using the ratio Aβ1-42/Aβ1-40. Quantification of t-Tau and p-Tau were not influenced by this pre-analytical condition.
CONCLUSION: The surface/volume ratio can potentially influence the results of amyloid AD biomarkers. It appears essential to take into account the surface/volume ratio of the storage tubes when quantifying CSF biomarkers in clinical routine.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid; Biomarkers; Cerebrospinal fluid; Lumipulse; Tau

Mesh:

Substances:

Year:  2018        PMID: 30579960     DOI: 10.1016/j.cca.2018.12.021

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.

Authors:  Michelle R Campbell; Susan Ashrafzadeh-Kian; Ronald C Petersen; Michelle M Mielke; Jeremy A Syrjanen; Argonde C van Harten; Val J Lowe; Clifford R Jack; Joshua A Bornhorst; Alicia Algeciras-Schimnich
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-18

2.  Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.

Authors:  Daniel Alcolea; Jordi Pegueroles; Laia Muñoz; Valle Camacho; Diego López-Mora; Alejandro Fernández-León; Nathalie Le Bastard; Els Huyck; Alicia Nadal; Verónica Olmedo; Frederic Sampedro; Victor Montal; Eduard Vilaplana; Jordi Clarimón; Rafael Blesa; Juan Fortea; Alberto Lleó
Journal:  Ann Clin Transl Neurol       Date:  2019-08-28       Impact factor: 4.511

3.  Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.

Authors:  Eline A J Willemse; Betty M Tijms; Bart N M van Berckel; Nathalie Le Bastard; Wiesje M van der Flier; Philip Scheltens; Charlotte E Teunissen
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-01

4.  Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.

Authors:  Ashvini Keshavan; Henrietta Wellington; Zhongbo Chen; Ayesha Khatun; Miles Chapman; Melanie Hart; David M Cash; William Coath; Thomas D Parker; Sarah M Buchanan; Sarah E Keuss; Matthew J Harris; Heidi Murray-Smith; Amanda Heslegrave; Nick C Fox; Henrik Zetterberg; Jonathan M Schott
Journal:  Alzheimers Dement (Amst)       Date:  2020-09-13

5.  The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone.

Authors:  Constance Delaby; Teresa Estellés; Nuole Zhu; Javier Arranz; Isabel Barroeta; María Carmona-Iragui; Ignacio Illán-Gala; Miguel Ángel Santos-Santos; Miren Altuna; Isabel Sala; M Belén Sánchez-Saudinós; Laura Videla; Sílvia Valldeneu; Andrea Subirana; Mireia Tondo; Francisco Blanco-Vaca; Sylvain Lehmann; Olivia Belbin; Rafael Blesa; Juan Fortea; Alberto Lleó; Daniel Alcolea
Journal:  Alzheimers Res Ther       Date:  2022-02-01       Impact factor: 6.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.